Dr. Eckstein joined TVM Capital in 2004, and is a General Partner in the firm’s life sciences practice where he focuses on earlier-stage investments. He is a member of the Board of Directors of CoNCERT Pharmaceuticals, Inc., Enanta Pharmaceuticals, Magen Biosciences, SelectX, Inc. and Ascent Therapeutics, served as an Advisor to Sirtris Pharmaceuticals.
As Director, Lead Discovery and Research IT at Enanta Pharmaceuticals, Inc., he directed the company's lead discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis and other autoimmune disorders. Prior to joining Enanta, he managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix, Inc. (now GPC-Biotech). At Mitotix he led the $48 million research collaboration with the BASF Bioresearch Corporation (BBC) on Cdc25 anticancer therapeutics.
Dr. Eckstein is an Alumni of the Kauffman Fellows Program (www.kauffmanfellows.com).
Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco (UCSF). The author of more than 20 scientific publications, Dr. Eckstein also holds several issued and pending patents. He is managing editor of Frontiers in Bioscience “Current Topics in Lead Discovery” and serves as an editorial board advisor for IDrugs. Dr. Eckstein is also an Advisor to the Alzheimer Research Forum (ARF) and a founding member of the Cure Dystonia Initiative Advisory Council (CDIAC).
